Product Code: LI_2110924 / A10559
The global medical thawing system market was valued at $165.82 million in 2019 and is expected to reach $279.17 million by 2027 with a CAGR of 11.6% during the forecast period.
Thawing system is the process developed to defrost biological samples in cell biology research. Biology research is used in drug discovery, bio-banking, assisted reproduction, cellular therapy, and regenerative medicine. This system is required to transport and store pharmaceutical products & services in the biopharmaceutical industry. Automated thawing instruments are designed to rapidly thaw live biological contents of a cryogenic vial with high reproducibility and minimal risk of contamination.
Increase in incidences of chronic disease lead to demand for blood and plasma products and technological advancements to simplify the process of thawing, which propels the market growth. In addition, rise in awareness and government initiatives toward plasma donation, rise in launches and agreement of medical thawing systems, increase in number of embryo donors, and rise in awareness of third-party reproduction further drive the market growth. However, high cost of automation hinders the market growth. Moreover, direct need for novel medicinal inventions to push adoption of thawing systems is expected to provide lucrative market growth during the forecast period.
The medical thawing system market is divided on the basis of sample type, end user, and region. By sample, the market is segmented into blood, embryo, ovum, and semen. On the basis of end user, it is segmented into blood banks, hospitals, tissue banks, pharmaceutical and biotech companies, and others. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Competitive rivalry in the global medical thawing system market was observed at high level as major market participants are focused on the adoption of growth strategies such as product launches, agreement and acquisitions to gain substantial share in the competitive market.
Prominent companies operating in the global medical thawing system market include Barkey GmbH & Co. KG, Boekel Scientific, BioLife Solutions Inc, Cardinal Health, Inc., General Electric Company, Helmer Scientific, Sartorius AG, Sarstedt AG & Co. KG, Terumo Corporation, and Thermo Fisher Scientific Inc.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global medical thawing system market with current trends and future estimations from 2019 to 2027 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Key Market Segments
By Sample Type
By End User
- Blood Banks
- Hospitals
- Tissue Banks
- Pharmaceutical and Biotech Companies
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- List of key players profiled in the report
- Barkey GmbH & Co. KG
- Boekel Scientific
- BioLife Solutions Inc.
- Cardinal Health, Inc.
- General Electric Company
- Helmer Scientific
- Sartorius AG
- Sarstedt AG & Co. KG
- Terumo Corporation
- Thermo Fisher Scientific Inc.
- List of the other key players (not included in the report) includesARCOX TMC GROUP, LABCOLD, Abbott, Medtronic, Brainlab AG, Varian Medical Systems, Inc., Olympus Corporation and KARL STORZ SE & Co. KG.
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
- 1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning, 2019
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.1.1.Increase in incidences of chronic disease leading to demand for blood and plasma products
- 3.5.1.2.Technological advancement to ease and simply the process of thawing
- 3.5.1.3.Rise in awareness and government initiative towards the plasma donation
- 3.5.1.1.Rise in launches and agreement of medical thawing systems
- 3.5.1.2.Increase in number of embryo donors and rise in awareness of third party reproduction
- 3.5.2.Restraints
- 3.5.2.1.High cost of the automation
- 3.5.3.Opportunities
- 3.5.3.1.Dire need for novel medicinal inventions to push adoption of thawing systems
- 3.5.4.Impact analysis
- 3.6.Impact analysis of COVID-19 on medical thawing system market
CHAPTER 4:MEDICAL THAWING SYSTEM MARKET, BY SAMPLE TYPE
- 4.1.Overview
- 4.1.1.Market size and forecast
- 4.2.Blood
- 4.2.1.Key developments and tends
- 4.2.2.Market size and forecast, by region
- 4.2.3.Market analysis, by country
- 4.3.Embryo
- 4.3.1.Key developments and tends
- 4.3.2.Market size and forecast, by region
- 4.3.3.Market analysis, by country
- 4.4.Ovum
- 4.4.1.Key market trends and opportunity
- 4.4.2.Market size and forecast, by region
- 4.4.3.Market analysis, by country
- 4.5.Semen
- 4.5.1.Key market trends and opportunity
- 4.5.2.Market size and forecast, by region
- 4.5.3.Market analysis, by country
CHAPTER 5:MEDICAL THAWING SYSTEM MARKET, BY END USER
- 5.1.Overview
- 5.1.1.Market size and forecast, by end user
- 5.2.Blood Banks
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
- 5.3.Hospitals
- 5.3.1.Market size and forecast, by region
- 5.3.2.Market analysis, by country
- 5.4.Tissue Banks
- 5.4.1.Market size and forecast, by region
- 5.4.2.Market analysis, by country
- 5.5.Pharmaceutical and Biotech Companies
- 5.5.1.Market size and forecast, by region
- 5.5.2.Market analysis, by country
- 5.6.Others
- 5.6.1.Market size and forecast, by region
- 5.6.2.Market analysis, by country
CHAPTER 6:MEDICAL THAWING SYSTEM MARKET, BY REGION
- 6.1.Overview
- 6.1.1.Market size and forecast
- 6.2.North America
- 6.2.1.Key market trends and opportunities
- 6.2.2.North America market size and forecast, by sample type
- 6.2.3.North America market size and forecast, by end user
- 6.2.4.North America market size and forecast, by country
- 6.2.5.U.S.
- 6.2.5.1.U.S. market size and forecast, by sample type
- 6.2.5.2.U.S. market size and forecast, by end user
- 6.2.6.Canada
- 6.2.6.1.Canada market size and forecast, by sample type
- 6.2.6.2.Canada market size and forecast, by end user
- 6.2.7.Mexico
- 6.2.7.1.Mexico market size and forecast, by sample type
- 6.2.7.2.Mexico market size and forecast, by end user
- 6.3.Europe
- 6.3.1.Key market trends and opportunities
- 6.3.2.Europe market size and forecast, by sample type
- 6.3.3.Europe market size and forecast, by end user
- 6.3.4.Europe market size and forecast, by country
- 6.3.5.Germany
- 6.3.5.1.Germany market size and forecast, by sample type
- 6.3.5.2.Germany market size and forecast, by end user
- 6.3.6.France
- 6.3.6.1.France market size and forecast, by sample type
- 6.3.6.2.France market size and forecast, by end user
- 6.3.7.UK
- 6.3.7.1.UK market size and forecast, by sample type
- 6.3.7.2.UK market size and forecast, by end user
- 6.3.8.Italy
- 6.3.8.1.Italy market size and forecast, by sample type
- 6.3.8.2.Italy market size and forecast, by end user
- 6.3.9.Spain
- 6.3.9.1.Spain market size and forecast, by sample type
- 6.3.9.2.Spain market size and forecast, by end user
- 6.3.10.Rest of Europe
- 6.3.10.1.Rest of Europe market size and forecast, by sample type
- 6.3.10.2.Rest of Europe market size and forecast, by end user
- 6.4.Asia-Pacific
- 6.4.1.Key market trends and opportunities
- 6.4.2.Asia-Pacific market size and forecast, by sample type
- 6.4.3.Asia-Pacific market size and forecast, by end user
- 6.4.4.Asia-Pacific market size and forecast, by country
- 6.4.5.Japan
- 6.4.5.1.Japan market size and forecast, by sample type
- 6.4.5.2.Japan market size and forecast, by end user
- 6.4.6.China
- 6.4.6.1.China market size and forecast, by sample type
- 6.4.6.2.China market size and forecast, by end user
- 6.4.7.Australia
- 6.4.7.1.Australia market size and forecast, by sample type
- 6.4.7.2.Australia market size and forecast, by end user
- 6.4.8.India
- 6.4.8.1.India market size and forecast, by sample type
- 6.4.8.2.India market size and forecast, by end user
- 6.4.9.South Korea
- 6.4.9.1.South Korea market size and forecast, by sample type
- 6.4.9.2.South Korea market size and forecast, by end user
- 6.4.10.Rest of Asia-Pacific
- 6.4.10.1.Rest of Asia-Pacific market size and forecast, by sample type
- 6.4.10.2.Rest of Asia-Pacific market size and forecast, by end user
- 6.5.LAMEA
- 6.5.1.Key market trends and opportunities
- 6.5.2.LAMEA market size and forecast, by sample type
- 6.5.3.LAMEA market size and forecast, by end user
- 6.5.4.LAMEA market size and forecast, by country
- 6.5.5.Brazil
- 6.5.5.1.Brazil market size and forecast, by sample type
- 6.5.5.2.Brazil market size and forecast, by end user
- 6.5.6.Saudi Arabia
- 6.5.6.1.Saudi Arabia market size and forecast, by sample type
- 6.5.6.2.Saudi Arabia market size and forecast, by end user
- 6.5.7.South Africa
- 6.5.7.1.South Africa market size and forecast, by sample type
- 6.5.7.2.South Africa market size and forecast, by end user
- 6.5.8.Rest of LAMEA
- 6.5.8.1.Rest of LAMEA market size and forecast, by sample type
- 6.5.8.2.Rest of LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
- 7.1.BARKEY GMBH & CO. KG
- 7.1.1.Company overview
- 7.1.2.Company snapshot
- 7.1.3.Operating business segments
- 7.1.4.Product portfolio
- 7.2.BOEKEL SCIENTIFIC
- 7.2.1.Company overview
- 7.2.2.Company snapshot
- 7.2.3.Operating business segments
- 7.2.4.Product portfolio
- 7.3.BIOLIFE SOLUTIONS INC.
- 7.3.1.Company overview
- 7.3.2.Company snapshot
- 7.3.3.Operating business segments
- 7.3.4.Product portfolio
- 7.3.5.Business performance
- 7.4.CARDINAL HEALTH INC.
- 7.4.1.Company overview
- 7.4.2.Company snapshot
- 7.4.3.Operating business segments
- 7.4.4.Product portfolio
- 7.4.5.Business performance
- 7.5.GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
- 7.5.1.Company overview
- 7.5.2.Company snapshot
- 7.5.3.Operating business segments
- 7.5.4.Product portfolio
- 7.5.5.Business performance
- 7.6.HELMER SCIENTIFIC
- 7.6.1.Company overview
- 7.6.2.Company snapshot
- 7.6.3.Operating business segments
- 7.6.4.Product portfolio
- 7.6.5.Business performance
- 7.7.SARTORIUS AG
- 7.7.1.Company overview
- 7.7.2.Company snapshot
- 7.7.3.Operating business segments
- 7.7.4.Product portfolio
- 7.7.5.Business performance
- 7.8.SARSTEDT AG & CO. KG
- 7.8.1.Company overview
- 7.8.2.Company snapshot
- 7.8.3.Operating business segments
- 7.8.4.Product portfolio
- 7.9.TERUMO CORPORATION
- 7.9.1.Company overview
- 7.9.2.Company snapshot
- 7.9.3.Operating business segments
- 7.9.4.Product portfolio
- 7.9.5.Business performance
- 7.10.THERMO FISHER SCIENTIFIC, INC.
- 7.10.1.Company overview
- 7.10.2.Company snapshot
- 7.10.3.Operating business segments
- 7.10.4.Product portfolio
- 7.10.5.Business performance